The Prevalence of Menstrual Cycle Disorders in Female Athletes from Different Sports Disciplines: A Rapid Review.
Gimunová M, Paulínyová A, Bernaciková M, Paludo AC.
Int J Environ Res Public Health. 2022 Oct 31;19(21):14243. doi: 10.3390/ijerph192114243.
Hyperprolactinemia: pathophysiology and therapeutic approach.
Capozzi A, Scambia G, Pontecorvi A, Lello S.
Gynecol Endocrinol. 2015 Jul;31(7):506-10. doi: 10.3109/09513590.2015.1017810. Epub 2015 Jul 6.
[Intensive training and menstrual disorders in young female: Impact on bone mass].
Maïmoun L, Paris F, Coste O, Sultan C.
Gynecol Obstet Fertil. 2016 Nov;44(11):659-663. doi: 10.1016/j.gyobfe.2016.09.001. Epub 2016 Oct 15.
Hyperprolactinemia.
Majumdar A, Mangal NS.
J Hum Reprod Sci. 2013 Jul;6(3):168-75. doi: 10.4103/0974-1208.121400.
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C.
Cochrane Database Syst Rev. 2018 May 24;5(5):CD010287. doi: 10.1002/14651858.CD010287.pub3.
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C.
Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4.
Oligomenorrhea and secondary amenorrhea in the adolescent.
Wentz AC.
Med Clin North Am. 1975 Nov;59(6):1385-94. doi: 10.1016/s0025-7125(16)31938-1.
[Lower bone density (osteopenia) in adolescent girls with oligomenorrhea and secondary amenorrhea].
Csermely T, Halvax L, Schmidt E, Zámbó K, Péterfai J, Vadon G, Szabó I.
Orv Hetil. 1997 Oct 26;138(43):2735-41.
Combined Lifestyle and Herbal Medicine in Overweight Women with Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial.
Arentz S, Smith CA, Abbott J, Fahey P, Cheema BS, Bensoussan A.
Phytother Res. 2017 Sep;31(9):1330-1340. doi: 10.1002/ptr.5858. Epub 2017 Jul 7.
Menstrual function in sports.
Roupas ND, Georgopoulos NA.
Hormones (Athens). 2011 Apr-Jun;10(2):104-16. doi: 10.14310/horm.2002.1300.
